Nikkei Japan, with 1.5M circulation, recently featured Silicon Valley-based Earli’s CEO and co-founder, Cyriac Roeding, in an op-ed exploring the need to shift from traditional early cancer detection and treatment methods based on often undruggable or completely missing natural cancer biomarkers to a new, engineering-led approach to cancer treatment.
The article outlines how Earli’s technology proposes a paradigm shift—bioengineering cancer cells to produce their own markers and trigger immune responses, opening a path to control cancer more effectively rather than chasing it. SKC is proud to help amplify this important message. Read the full article in Nikkei Japan.